Research analysts covering Valeant Pharmaceuticals International, Inc. (NYSE:VRX) are projecting that the shares reach $42 within the next 12-18 months. This is the consensus number derived from the 11 analyst reports taken into consideration. The most bullish, or aggressive analyst target pins the projected price at $81, while the most bearish, or conservative analyst sees the stock reaching $22.
Broker Rating Update on Valeant Pharmaceuticals International, Inc. (NYSE:VRX)
Zacks provides analysts with an Average Broker Rating (or ABR), basing it on sell-side recommendations. Shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) currently have an ABR of 2.61. This is based on a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell. Moving to earnings estimates, for this current fiscal period, Wall Street analysts have projected that the company will post $1.81 earnings per share. This is the current Zacks consensus EPS which was calculated at the time of writing. Analysts will likely revise their estimates leading in to the actual results date.
taking a look at the most recent period, which closed on 2016-06-30, Valeant Pharmaceuticals International, Inc. reported EPS of $1.4 for a surprise factor of -11.95%, calculated by being $-0.19 away from analyst projections.
Investors will be marking their calendars for 2016-10-17, when the company is planning to release their quarterly results.
The Wall Street analysts who cover The Coca-Cola Co (NYSE:KO) shares are providing price target projections on the company. They project that the shares will move to $47 within the upcoming year. The number they've arrived at is calculated by Zacks.com, long known as a provider of top-notch investment research. From the analysts polled by Zack's Research, the highest estimate stands at $52 and the lowest is at $40 for the stock.
Analyst Ratings In View
Zacks provides the average brokerage recommendation (ABR) for thousands of stocks for institutions and retail investors alike. This the calculated average of the actual recommendations (strong buy, hold, sell etc.) made for a given stock. The ABR is typically displayed with decimals (e.g. 1.52) versus the Zacks Rank, which is only shown in whole numbers (e.g. 1, 2, 3, etc.). This simplifies brokerage recommendations, which can become complicated. The Coca-Cola Co (NYSE:KO)'s shares currently have an ABR of 2.35.
During this fiscal period, Street analysts are projecting $0.49 earnings/share. This represents the current Zacks consensus EPS. For the period which closed on 2016-06-30, The Coca-Cola Co (NYSE:KO) dialed in an EPS of $0.6, creating a Surprise Factor of 3.45% (the difference between analyst projections and actual numbers). Curious investors will be awaiting 2016-10-19, the date when The Coca-Cola Co (NYSE:KO) will release their quarterly results.